 Saketh Guntupalli
Concepts (269)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 18 | 2023 | 144 | 4.380 |
Why?
| | Ovarian Neoplasms | 14 | 2023 | 420 | 3.370 |
Why?
| | Gynecology | 8 | 2021 | 184 | 2.700 |
Why?
| | Carcinoma, Endometrioid | 11 | 2023 | 47 | 2.410 |
Why?
| | Genital Neoplasms, Female | 6 | 2021 | 72 | 2.390 |
Why?
| | Hysterectomy | 11 | 2020 | 117 | 2.220 |
Why?
| | Fellowships and Scholarships | 5 | 2018 | 250 | 2.010 |
Why?
| | Uterine Cervical Neoplasms | 8 | 2021 | 216 | 1.960 |
Why?
| | Obstetrics | 4 | 2020 | 162 | 1.840 |
Why?
| | Enoxaparin | 3 | 2020 | 51 | 1.630 |
Why?
| | Internship and Residency | 6 | 2020 | 1001 | 1.610 |
Why?
| | Pyridones | 3 | 2020 | 119 | 1.570 |
Why?
| | Venous Thromboembolism | 3 | 2023 | 234 | 1.440 |
Why?
| | Pyrazoles | 3 | 2020 | 363 | 1.340 |
Why?
| | Sexual Dysfunction, Physiological | 2 | 2020 | 60 | 1.280 |
Why?
| | Anticoagulants | 3 | 2023 | 559 | 1.260 |
Why?
| | Clinical Competence | 5 | 2020 | 951 | 1.240 |
Why?
| | Lymph Nodes | 3 | 2017 | 455 | 1.220 |
Why?
| | Postoperative Complications | 6 | 2020 | 2235 | 1.050 |
Why?
| | Uterine Neoplasms | 3 | 2021 | 76 | 0.940 |
Why?
| | Neoplasm Staging | 17 | 2023 | 1221 | 0.920 |
Why?
| | Treatment Adherence and Compliance | 1 | 2021 | 20 | 0.800 |
Why?
| | Education, Medical, Graduate | 2 | 2016 | 399 | 0.800 |
Why?
| | Pulmonary Embolism | 1 | 2023 | 183 | 0.780 |
Why?
| | Neoplasm Recurrence, Local | 8 | 2021 | 900 | 0.770 |
Why?
| | Female | 56 | 2023 | 61547 | 0.770 |
Why?
| | Carcinosarcoma | 3 | 2017 | 17 | 0.750 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 1390 | 0.750 |
Why?
| | Middle Aged | 38 | 2023 | 27607 | 0.740 |
Why?
| | Robotic Surgical Procedures | 3 | 2016 | 89 | 0.720 |
Why?
| | Intrauterine Devices | 1 | 2019 | 24 | 0.700 |
Why?
| | Healthcare Disparities | 3 | 2021 | 495 | 0.670 |
Why?
| | Ovariectomy | 4 | 2015 | 124 | 0.670 |
Why?
| | Venous Thrombosis | 1 | 2020 | 147 | 0.660 |
Why?
| | Laparotomy | 2 | 2015 | 106 | 0.650 |
Why?
| | Oncologists | 1 | 2018 | 31 | 0.640 |
Why?
| | Aged | 29 | 2021 | 19644 | 0.640 |
Why?
| | Quality of Health Care | 2 | 2021 | 586 | 0.600 |
Why?
| | Neoplasm Invasiveness | 6 | 2021 | 462 | 0.600 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2017 | 31 | 0.590 |
Why?
| | Attitude | 1 | 2018 | 231 | 0.570 |
Why?
| | Minority Groups | 1 | 2018 | 237 | 0.570 |
Why?
| | Humans | 59 | 2023 | 118931 | 0.570 |
Why?
| | Neoplasms | 4 | 2023 | 2177 | 0.540 |
Why?
| | Aged, 80 and over | 13 | 2021 | 6555 | 0.530 |
Why?
| | Retrospective Studies | 15 | 2021 | 12972 | 0.530 |
Why?
| | Medication Adherence | 1 | 2020 | 555 | 0.530 |
Why?
| | Endometrium | 2 | 2019 | 61 | 0.520 |
Why?
| | Radiography, Thoracic | 1 | 2016 | 164 | 0.510 |
Why?
| | Hemostasis, Surgical | 1 | 2014 | 22 | 0.500 |
Why?
| | Abdominal Abscess | 1 | 2014 | 27 | 0.500 |
Why?
| | Gelatin | 1 | 2014 | 35 | 0.500 |
Why?
| | Surgeons | 1 | 2018 | 243 | 0.490 |
Why?
| | Interpersonal Relations | 1 | 2017 | 345 | 0.470 |
Why?
| | Thrombin | 1 | 2014 | 143 | 0.470 |
Why?
| | WT1 Proteins | 1 | 2013 | 12 | 0.450 |
Why?
| | Robotics | 1 | 2014 | 83 | 0.450 |
Why?
| | Estrogen Receptor beta | 1 | 2013 | 37 | 0.440 |
Why?
| | Adenocarcinoma | 3 | 2021 | 811 | 0.430 |
Why?
| | Prognosis | 9 | 2023 | 3440 | 0.410 |
Why?
| | Adult | 24 | 2021 | 31508 | 0.400 |
Why?
| | Lymphatic Vessels | 1 | 2011 | 54 | 0.390 |
Why?
| | Adenocarcinoma, Clear Cell | 2 | 2023 | 14 | 0.390 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2022 | 76 | 0.370 |
Why?
| | Disease-Free Survival | 6 | 2019 | 648 | 0.360 |
Why?
| | Preoperative Care | 3 | 2017 | 332 | 0.360 |
Why?
| | Lymph Node Excision | 3 | 2017 | 158 | 0.350 |
Why?
| | Smooth Muscle Tumor | 1 | 2009 | 5 | 0.350 |
Why?
| | Leiomyosarcoma | 1 | 2009 | 23 | 0.350 |
Why?
| | Sarcoma, Alveolar Soft Part | 1 | 2008 | 7 | 0.330 |
Why?
| | United States | 13 | 2021 | 12541 | 0.320 |
Why?
| | Survival Rate | 6 | 2021 | 1720 | 0.320 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 49 | 0.310 |
Why?
| | Neoplasm Grading | 7 | 2019 | 258 | 0.310 |
Why?
| | Neoplasms, Second Primary | 2 | 2019 | 92 | 0.300 |
Why?
| | Radiotherapy, Adjuvant | 3 | 2018 | 189 | 0.300 |
Why?
| | Combined Modality Therapy | 3 | 2020 | 1166 | 0.290 |
Why?
| | Insurance, Health | 3 | 2018 | 244 | 0.290 |
Why?
| | Cross-Sectional Studies | 5 | 2017 | 4551 | 0.290 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2018 | 360 | 0.290 |
Why?
| | Young Adult | 7 | 2021 | 10793 | 0.280 |
Why?
| | Pregnancy Complications | 2 | 2014 | 448 | 0.280 |
Why?
| | Cohort Studies | 5 | 2021 | 5116 | 0.270 |
Why?
| | Insurance Coverage | 2 | 2018 | 208 | 0.270 |
Why?
| | Databases, Factual | 3 | 2021 | 1231 | 0.260 |
Why?
| | Risk Factors | 6 | 2023 | 8998 | 0.260 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 307 | 0.250 |
Why?
| | Self Report | 2 | 2018 | 699 | 0.240 |
Why?
| | Nomograms | 2 | 2021 | 48 | 0.240 |
Why?
| | Follow-Up Studies | 6 | 2018 | 4596 | 0.230 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2210 | 0.220 |
Why?
| | Adolescent | 6 | 2021 | 18480 | 0.220 |
Why?
| | Liver Diseases | 1 | 2005 | 282 | 0.220 |
Why?
| | Length of Stay | 3 | 2015 | 1032 | 0.220 |
Why?
| | Platinum | 1 | 2022 | 38 | 0.210 |
Why?
| | Organ Sparing Treatments | 2 | 2019 | 31 | 0.210 |
Why?
| | Program Evaluation | 2 | 2018 | 843 | 0.210 |
Why?
| | Biomarkers, Tumor | 3 | 2019 | 1059 | 0.210 |
Why?
| | Paclitaxel | 5 | 2021 | 195 | 0.200 |
Why?
| | Quality of Life | 3 | 2020 | 2363 | 0.200 |
Why?
| | BRCA2 Protein | 1 | 2021 | 44 | 0.190 |
Why?
| | BRCA1 Protein | 1 | 2021 | 57 | 0.190 |
Why?
| | Ovary | 2 | 2019 | 205 | 0.190 |
Why?
| | Treatment Outcome | 5 | 2020 | 9341 | 0.190 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2019 | 15 | 0.180 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 40 | 0.180 |
Why?
| | Postoperative Hemorrhage | 1 | 2020 | 79 | 0.180 |
Why?
| | Withholding Treatment | 1 | 2020 | 67 | 0.180 |
Why?
| | NM23 Nucleoside Diphosphate Kinases | 1 | 2019 | 2 | 0.170 |
Why?
| | Pregnancy | 4 | 2020 | 5690 | 0.170 |
Why?
| | Peritoneal Neoplasms | 1 | 2019 | 53 | 0.170 |
Why?
| | Age Factors | 4 | 2016 | 2995 | 0.170 |
Why?
| | Cancer Survivors | 1 | 2023 | 199 | 0.170 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1243 | 0.160 |
Why?
| | Fibrinolytic Agents | 1 | 2020 | 238 | 0.160 |
Why?
| | Risk Assessment | 3 | 2019 | 3055 | 0.160 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 333 | 0.160 |
Why?
| | Stathmin | 1 | 2017 | 2 | 0.150 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2017 | 10 | 0.150 |
Why?
| | Health Status Disparities | 2 | 2017 | 209 | 0.150 |
Why?
| | Blood Loss, Surgical | 2 | 2015 | 87 | 0.150 |
Why?
| | Carcinoma | 1 | 2019 | 204 | 0.150 |
Why?
| | beta Catenin | 1 | 2019 | 219 | 0.150 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1128 | 0.150 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2017 | 24 | 0.150 |
Why?
| | Societies, Medical | 1 | 2021 | 703 | 0.150 |
Why?
| | Perioperative Care | 1 | 2018 | 132 | 0.150 |
Why?
| | Guideline Adherence | 1 | 2021 | 523 | 0.150 |
Why?
| | Case-Control Studies | 4 | 2019 | 3171 | 0.150 |
Why?
| | Neonatology | 1 | 2016 | 19 | 0.140 |
Why?
| | Benzamides | 1 | 2017 | 176 | 0.140 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2016 | 43 | 0.140 |
Why?
| | Surgical Oncology | 1 | 2016 | 14 | 0.140 |
Why?
| | Uterus | 2 | 2023 | 194 | 0.140 |
Why?
| | Marriage | 1 | 2017 | 109 | 0.140 |
Why?
| | Reimbursement Mechanisms | 1 | 2016 | 79 | 0.140 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2021 | 609 | 0.140 |
Why?
| | Piperidines | 1 | 2017 | 171 | 0.140 |
Why?
| | Bevacizumab | 3 | 2021 | 124 | 0.130 |
Why?
| | Drug Costs | 1 | 2016 | 94 | 0.130 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2015 | 13 | 0.130 |
Why?
| | Incidence | 2 | 2019 | 2424 | 0.130 |
Why?
| | Female Urogenital Diseases | 1 | 2014 | 5 | 0.130 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2015 | 51 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 348 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 339 | 0.130 |
Why?
| | Morbidity | 1 | 2015 | 296 | 0.130 |
Why?
| | Peritoneal Cavity | 1 | 2014 | 23 | 0.130 |
Why?
| | Intraoperative Complications | 1 | 2015 | 131 | 0.120 |
Why?
| | Surgical Wound Dehiscence | 1 | 2014 | 19 | 0.120 |
Why?
| | Blood Volume | 1 | 2014 | 58 | 0.120 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 304 | 0.120 |
Why?
| | Maternal-Fetal Exchange | 1 | 2015 | 157 | 0.120 |
Why?
| | Hemostatics | 1 | 2014 | 50 | 0.120 |
Why?
| | Drainage | 1 | 2014 | 157 | 0.120 |
Why?
| | Referral and Consultation | 1 | 2018 | 648 | 0.120 |
Why?
| | Colposcopy | 1 | 2013 | 17 | 0.120 |
Why?
| | Needs Assessment | 1 | 2015 | 327 | 0.120 |
Why?
| | Cisplatin | 3 | 2020 | 271 | 0.120 |
Why?
| | Health Policy | 1 | 2016 | 332 | 0.110 |
Why?
| | Patient Readmission | 1 | 2018 | 634 | 0.110 |
Why?
| | Antibodies | 1 | 2015 | 392 | 0.110 |
Why?
| | Early Detection of Cancer | 1 | 2016 | 360 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1353 | 0.100 |
Why?
| | Clinical Trials as Topic | 1 | 2016 | 969 | 0.100 |
Why?
| | Surgical Wound Infection | 1 | 2014 | 251 | 0.100 |
Why?
| | Proportional Hazards Models | 3 | 2021 | 1125 | 0.100 |
Why?
| | Fetus | 1 | 2015 | 689 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 841 | 0.090 |
Why?
| | Male | 6 | 2020 | 57784 | 0.090 |
Why?
| | Carboplatin | 2 | 2021 | 142 | 0.090 |
Why?
| | Benzimidazoles | 2 | 2021 | 140 | 0.090 |
Why?
| | Multicenter Studies as Topic | 2 | 2021 | 253 | 0.090 |
Why?
| | Prospective Studies | 5 | 2021 | 6471 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1473 | 0.080 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 4705 | 0.080 |
Why?
| | Metrorrhagia | 1 | 2008 | 5 | 0.080 |
Why?
| | Dilatation and Curettage | 1 | 2008 | 10 | 0.080 |
Why?
| | Pediatrics | 1 | 2016 | 985 | 0.080 |
Why?
| | Quality Improvement | 1 | 2015 | 963 | 0.080 |
Why?
| | SEER Program | 2 | 2018 | 205 | 0.070 |
Why?
| | Models, Biological | 1 | 2014 | 1715 | 0.070 |
Why?
| | Rupture, Spontaneous | 1 | 2005 | 18 | 0.070 |
Why?
| | Budd-Chiari Syndrome | 1 | 2005 | 9 | 0.070 |
Why?
| | HELLP Syndrome | 1 | 2005 | 6 | 0.070 |
Why?
| | Hepatolenticular Degeneration | 1 | 2005 | 18 | 0.070 |
Why?
| | Hematoma | 1 | 2005 | 51 | 0.070 |
Why?
| | Hepatitis B | 1 | 2005 | 52 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1510 | 0.060 |
Why?
| | Obesity | 2 | 2016 | 2746 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2436 | 0.060 |
Why?
| | Colorado | 1 | 2014 | 4193 | 0.060 |
Why?
| | Cost-Benefit Analysis | 2 | 2020 | 554 | 0.060 |
Why?
| | Decision Support Techniques | 2 | 2020 | 364 | 0.060 |
Why?
| | Pre-Eclampsia | 1 | 2005 | 183 | 0.060 |
Why?
| | Hepatitis C | 1 | 2005 | 217 | 0.060 |
Why?
| | Fatty Liver | 1 | 2005 | 253 | 0.060 |
Why?
| | Acute Disease | 1 | 2005 | 940 | 0.050 |
Why?
| | Cholestasis | 1 | 2005 | 228 | 0.050 |
Why?
| | Medical Futility | 1 | 2022 | 22 | 0.050 |
Why?
| | Claudin-4 | 1 | 2022 | 9 | 0.050 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 16 | 0.050 |
Why?
| | Critical Care | 1 | 2005 | 492 | 0.050 |
Why?
| | Genes, BRCA2 | 1 | 2021 | 25 | 0.050 |
Why?
| | Genes, BRCA1 | 1 | 2021 | 31 | 0.050 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2021 | 47 | 0.050 |
Why?
| | Hematologic Diseases | 1 | 2021 | 60 | 0.050 |
Why?
| | Life Style | 1 | 2023 | 430 | 0.050 |
Why?
| | Organoplatinum Compounds | 1 | 2020 | 41 | 0.050 |
Why?
| | Topotecan | 1 | 2020 | 13 | 0.050 |
Why?
| | DNA Repair | 1 | 2022 | 198 | 0.050 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 103 | 0.050 |
Why?
| | Injections, Intraperitoneal | 1 | 2019 | 108 | 0.040 |
Why?
| | DNA Damage | 1 | 2022 | 357 | 0.040 |
Why?
| | Japan | 1 | 2019 | 97 | 0.040 |
Why?
| | Injections, Intravenous | 1 | 2019 | 210 | 0.040 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 23 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 31 | 0.040 |
Why?
| | DNA Polymerase II | 1 | 2019 | 29 | 0.040 |
Why?
| | Platinum Compounds | 1 | 2019 | 11 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2020 | 380 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 80 | 0.040 |
Why?
| | Angiogenesis Inhibitors | 1 | 2020 | 219 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 143 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 251 | 0.040 |
Why?
| | Administration, Oral | 1 | 2020 | 756 | 0.040 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2019 | 180 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 1266 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 254 | 0.040 |
Why?
| | Health Facility Size | 1 | 2016 | 12 | 0.040 |
Why?
| | Hospitals, Private | 1 | 2016 | 12 | 0.040 |
Why?
| | Time Factors | 2 | 2017 | 6409 | 0.040 |
Why?
| | Social Class | 1 | 2017 | 218 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2016 | 104 | 0.030 |
Why?
| | Doxorubicin | 1 | 2017 | 302 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2019 | 568 | 0.030 |
Why?
| | Odds Ratio | 1 | 2018 | 995 | 0.030 |
Why?
| | Ileus | 1 | 2015 | 10 | 0.030 |
Why?
| | Medically Uninsured | 1 | 2016 | 125 | 0.030 |
Why?
| | Salpingectomy | 1 | 2015 | 13 | 0.030 |
Why?
| | Diet | 1 | 2023 | 1154 | 0.030 |
Why?
| | Income | 1 | 2016 | 173 | 0.030 |
Why?
| | Urinary Retention | 1 | 2015 | 19 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 455 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 1944 | 0.030 |
Why?
| | Elective Surgical Procedures | 1 | 2016 | 160 | 0.030 |
Why?
| | Advisory Committees | 1 | 2016 | 212 | 0.030 |
Why?
| | Pelvis | 1 | 2015 | 92 | 0.030 |
Why?
| | Critical Pathways | 1 | 2014 | 78 | 0.030 |
Why?
| | Urban Population | 1 | 2016 | 409 | 0.030 |
Why?
| | Papanicolaou Test | 1 | 2013 | 40 | 0.030 |
Why?
| | Vaginal Smears | 1 | 2013 | 49 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2014 | 238 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1691 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2015 | 349 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2019 | 1055 | 0.030 |
Why?
| | Rural Population | 1 | 2016 | 452 | 0.030 |
Why?
| | Exercise | 1 | 2023 | 1655 | 0.030 |
Why?
| | Disease Progression | 1 | 2019 | 2490 | 0.030 |
Why?
| | Comorbidity | 1 | 2016 | 1525 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2061 | 0.020 |
Why?
| | Biomedical Research | 1 | 2016 | 612 | 0.020 |
Why?
| | Curriculum | 1 | 2016 | 910 | 0.020 |
Why?
| | Colorectal Neoplasms | 1 | 2016 | 628 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2016 | 940 | 0.020 |
Why?
| | Patient Discharge | 1 | 2015 | 796 | 0.020 |
Why?
| | Mutation | 1 | 2019 | 3457 | 0.020 |
Why?
| | Breast Neoplasms | 1 | 2016 | 1964 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2015 | 5255 | 0.020 |
Why?
|
|
Guntupalli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|